This session will review the most up to date information on the treatment of psoriasis patients including the pipeline of new therapeutic agents and a strategy of selecting the very best drug for each patient. The treatment of psoriasis in special populations including women of childbearing potential, pregnant women and children can be challenging. The latest from the new Guidelines of Care for these populations will be included. What do you need to know about the risk of malignancy with biologic therapy? Should you treat to target? Will treatment influence the cardiovascular comorbidities?
Dr. Elewski / Welcome and Overview
Dr. Lebwohl / Treatment of psoriasis: Which drug for which patient?
Dr. Blauvelt / Pipeline of new therapeutic agents
Dr. Kimball / Treatment of psoriasis in pregnancy
Dr. Cordoro / Treatment of pediatric psoriasis: Update on new guidelines of care
Dr. Wu / Does psoriasis treatment influence the cardiovascular comorbidities?
Dr. Langley / Treat to Target: Of course, we should!
Dr. Gordon / Treat to Target: No, not necessarily!
Dr. Langley and Dr. Gordon / Rebuttals and Audience voting
Dr. Strober / The risk of malignancy with biologic therapy for psoriasis
Dr. Blauvelt, Dr. Wu, Dr. Langley, Dr. Gordon, Dr. Elewski, and Dr. Armstrong / Panel discussion